Identification of New Markers in the Hypereosinophilic Syndrome
SHE
2 other identifiers
interventional
41
1 country
1
Brief Summary
The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2010
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 29, 2010
CompletedFirst Submitted
Initial submission to the registry
October 22, 2012
CompletedFirst Posted
Study publicly available on registry
October 24, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedJanuary 8, 2026
January 1, 2026
5 years
October 22, 2012
January 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.
one month after patient inclusion
Study Arms (3)
Hypereosinophilic syndrome unexplained
EXPERIMENTALHypereosinophilic syndrome explained
ACTIVE COMPARATORNormal rate of eosinophilic
SHAM COMPARATORInterventions
comparison of biomarkers between HES, HE biomarkers data and control arms
Eligibility Criteria
You may qualify if:
- dated and signed informed consent
- virale serology negative or negative result less than 6 months
- virale serology negative for HBV or vaccinated patient
- insured
- virale serology negative or negative result less than 6 months
- negative pregnancy test or female menopause for at least 1 year
You may not qualify if:
- subject enable adult, under guardianship or under protective measures of justice
- Refusal or inability to give informed consent
- The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU, Hôpital Claude Huriez
Lille, Nord, 59037, France
Related Publications (1)
Lefevre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Salle D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE; French Eosinophil Network. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica. 2015 Aug;100(8):1086-95. doi: 10.3324/haematol.2014.118042. Epub 2015 Feb 14.
PMID: 25682606RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lionel Prin, MD PhD
University Hospital, Lille
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2012
First Posted
October 24, 2012
Study Start
June 29, 2010
Primary Completion
July 1, 2015
Study Completion
July 1, 2015
Last Updated
January 8, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share